HAEMONETICS CORP — Director's Dealing 2016

Aug 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2016-08-16

Reporting Person: Simon, Christopher (President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-16	Performance Shares	$34.9959	A	57149	Acquired	2019-12-31	Common Stock (57149)	Direct

Footnotes

F1: This grant was made under the terms of Mr. Simon's Employment Agreement and is the matching grant for his August 4, 2016 open market purchase of Haemonetics Corporation common shares. These Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to companies in the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance during a three year period beginning August 4, 2016. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.